These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 29861296)

  • 1. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
    McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
    Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
    Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
    Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
    Kadoch C; Crabtree GR
    Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
    Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
    PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
    Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
    Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies.
    Boulay G; Cironi L; Garcia SP; Rengarajan S; Xing YH; Lee L; Awad ME; Naigles B; Iyer S; Broye LC; Keskin T; Cauderay A; Fusco C; Letovanec I; Chebib I; Nielsen PG; Tercier S; Cherix S; Nguyen-Ngoc T; Cote G; Choy E; Provero P; Suvà ML; Rivera MN; Stamenkovic I; Riggi N
    Life Sci Alliance; 2021 Feb; 4(2):. PubMed ID: 33361335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
    Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
    Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
    El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
    Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
    Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
    Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
    Raquib AR; Hofvander J; Ta M; Nielsen TO
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
    Banito A; Li X; Laporte AN; Roe JS; Sanchez-Vega F; Huang CH; Dancsok AR; Hatzi K; Chen CC; Tschaharganeh DF; Chandwani R; Tasdemir N; Jones KB; Capecchi MR; Vakoc CR; Schultz N; Ladanyi M; Nielsen TO; Lowe SW
    Cancer Cell; 2018 Mar; 33(3):527-541.e8. PubMed ID: 29502955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas.
    Cheng Y; Shen Z; Gao Y; Chen F; Xu H; Mo Q; Chu X; Peng CL; McKenzie TT; Palacios BE; Hu J; Zhou H; Long J
    Nat Commun; 2022 May; 13(1):2724. PubMed ID: 35585082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
    Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
    Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
    Floros KV; Fairchild CK; Li J; Zhang K; Roberts JL; Kurupi R; Hu B; Kraskauskiene V; Hosseini N; Shen S; Inge MM; Smith-Fry K; Li L; Sotiriou A; Dalton KM; Jose A; Abdelfadiel EI; Xing Y; Hill RD; Slaughter JM; Shende M; Lorenz MR; Hinojosa MR; Belvin BR; Lai Z; Boikos SA; Stamatouli AM; Lewis JP; Manjili MH; Valerie K; Li R; Banito A; Poklepovic A; Koblinski JE; Siggers T; Dozmorov MG; Jones KB; Radhakrishnan SK; Faber AC
    Res Sq; 2024 Jun; ():. PubMed ID: 38883782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
    Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
    Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
    Floros KV; Fairchild CK; Li J; Zhang K; Roberts JL; Kurupi R; Hu B; Kraskauskiene V; Hosseini N; Shen S; Inge MM; Smith-Fry K; Li L; Sotiriou A; Dalton KM; Jose A; Abdelfadiel EI; Xing Y; Hill RD; Slaughter JM; Shende M; Lorenz MR; Hinojosa MR; Belvin BR; Lai Z; Boikos SA; Stamatouli AM; Lewis JP; Manjili MH; Valerie K; Li R; Banito A; Poklepovic A; Koblinski JE; Siggers T; Dozmorov MG; Jones KB; Radhakrishnan SK; Faber AC
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.